Post‐transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 <scp>HLA</scp>‐mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the <scp>ALWP</scp> of the <scp>EBMT</scp>

Wieczorek, Michele; Labopin, Myriam; Castagna, Luca; Brissot, Éolia; Socié, Gérard; Raiola, Anna Maria; Angelucci, Emanuele; Rodríguez, Arancha Bermúdez; Yakoub‐Agha, Ibrahim; Aljurf, Mahmoud; Crawley, Charles; Mear, Jean Baptiste; Musso, Maurizio; Fanin, Renato; Avenoso, Daniele; Turlure, Pascal; Tecchio, Cristina; Sanz, Jaime; Ciceri, Fabio; Nagler, Arnon; Mohty, Mohamad

doi:10.1002/ajh.26782

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of donors for HAPLO are first-degree (FD) related family members such as parents, children or siblings. If a suitable FD related donor is not available, non-first-degree (NFD) related donors, or in very rare occasions related donors with more than 5/10 HLA mismatch [6], have sometimes been used. Previous small studies performed by either the Baltimore [7] or the Beijing team [8,9] have indicated the feasibility of NFD HAPLO.…”

Section: To the Editormentioning

confidence: 99%

“…Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Yishan Ye 1 , Myriam Labopin 2 , Jia Chen 3 , Zafer Gulbas 4 , Xi Zhang 5 , Yener Koc 6 , Didier Blaise 7 , Fabio Ciceri 8 , Emmanuelle Polge 2 , Mohamed Houhou 2 , Lin Li 1 , Yi Luo 1 , Depei Wu 3 , He Huang 1* , Mohamad Mohty 2,9,10* and Norbert-Claude Gorin 2,9,10* (NFD, 50.9% vs. FD, 47.8%; p = 0.69) also showed no significant differences. The two cohorts showed no difference in terms of cumulative day 180 grade II-IV, grade III-IV acute GVHD, 2-year cumulative incidences of chronic and extensive chronic GVHD.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Labopin

Chen

et al. 2023

J Hematol Oncol

View full text Add to dashboard Cite

There are situations where non-first-degree (NFD) related donors have to be considered as alternatives to first-degree (FD) related donors for haploidentical hematopoietic cell transplantation (HAPLO). However, the efficacy of these NFD related transplants remains uncertain. All consecutive adult patients (≥ 18 years) with acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL) in CR who underwent a first HAPLO between 2010 and 2021 in the European Society for Blood and Marrow Transplantation (EBMT) registry were analyzed. Exact matching and propensity score matching was used. The NFD-to-FD ratio was 1:3. 2703 patients (AML: n = 2047; ALL: n = 656) in CR received a first HAPLO from either NFD (n = 154) or FD (n = 2549) related donors in 177 EBMT centers. 123 NFD and 324 FD HAPLO were included for analysis after matching. Median patient age was 35.6 and 37.2 for the NFD and FD cohorts, respectively. Both cohorts reached good engraftment rates (NFD: 95.7% vs. FD, 95.6%; p = 0.78). The 2-year relapse incidence (NFD, 21.1% vs. FD, 22.6%; p = 0.84) and non-relapse mortality (NRM) (NFD, 13.2% vs. FD, 17.7%; p = 0.33) were not significantly different. The 2-year overall survival (OS) (NFD, 71.8% vs. FD, 68.3%; p = 0.56), leukemia-free survival (LFS) (NFD, 65.7% vs. FD, 59.7%; p = 0.6) and graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) (NFD, 50.9% vs. FD, 47.8%; p = 0.69) also showed no significant differences. The two cohorts showed no difference in terms of cumulative day 180 grade II-IV, grade III-IV acute GVHD, 2-year cumulative incidences of chronic and extensive chronic GVHD. For HAPLO in patients with acute leukemia, NFD related donors could be equivalent substitutions when FD related donors are not available.

show abstract